Research programme: antibacterial potentiator therapeutics - Spero Therapeutics

Drug Profile

Research programme: antibacterial potentiator therapeutics - Spero Therapeutics

Alternative Names: Potentiator programme - Spero; SPR-206

Latest Information Update: 23 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northern Antibiotics
  • Developer Evotec AG; Spero Therapeutics
  • Class Antibacterials; Peptides; Small molecules
  • Mechanism of Action Bacterial outer membrane protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections; Intra-abdominal infections; Urinary tract infections

Most Recent Events

  • 20 Jun 2016 Preclinical trials in Gram-negative infections in USA (unspecified route)
  • 08 Jun 2016 Spero Therapeutics plans a clinical trial for Gram-negative infections
  • 15 Dec 2015 Spero Therapeutics and Evotec AG agree to co-develop antibacterial potentiator therapeutics for Gram-negative infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top